Instil Bio, Inc. (TIL)

NASDAQ: TIL · IEX Real-Time Price · USD
-0.007 (-1.79%)
Sep 28, 2023, 9:30 AM EDT - Market open

Company Description

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer.

The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its lead product is ITIL-306, a Co-Stimulatory Antigen Receptor molecule to recognize folate receptor alpha, a tumor-associated antigen that is expressed on various solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.

The company was incorporated in 2018 and is headquartered in Dallas, Texas.

Instil Bio, Inc.
Instil Bio logo
Country United States
Founded 2018
IPO Date Mar 19, 2021
Industry Biotechnology
Sector Healthcare
Employees 192
CEO Bronson Crouch

Contact Details

3963 Maple Avenue, Suite 350
Dallas, Texas 75219
United States
Phone (972) 499-3350

Stock Details

Ticker Symbol TIL
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $20.00
CIK Code 0001789769
CUSIP Number 45783C101
ISIN Number US45783C1018
Employer ID 83-2072195
SIC Code 2836

Key Executives

Name Position
Bronson Crouch Chairman and Chief Executive Officer
Dr. Sandeep Laumas M.D. Chief Financial Officer and Chief Business Officer
Timothy L. Moore Chief Operating Officer
Dr. Mark E. Dudley Ph.D. Chief Scientific Officer
Sumita Ray J.D. Chief Legal, Compliance, and Administrative Officer
Dr. Robert Hawkins MBBS, Ph.D. Head of Research & Development

Latest SEC Filings

Date Type Title
Aug 14, 2023 10-Q Quarterly Report
Aug 14, 2023 8-K Current Report
Jun 26, 2023 8-K Current Report
Jun 14, 2023 8-K Current Report
May 11, 2023 10-Q Quarterly Report
May 11, 2023 8-K Current Report
Apr 28, 2023 DEFR14A Filing
Apr 24, 2023 ARS Filing
Apr 24, 2023 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 24, 2023 DEF 14A Other definitive proxy statements